**PATENT** 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(MBHB Case No. 00-1213; A-636B)

Saris et al.

Serial No.: 09/724,583

Filed: November 28, 2000

For: Nucleic Acids Encoding
Interleukin-1 Receptor Antagonist-

Related Proteins and Uses Thereof

# UNDER 37 C.F.R. §1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### Dear Sir:

In order to comply with discretionary regulations 37 CFR §§1.97 and 1.98, attached hereto is Form PTO-1449 and copies of the documents listed thereon. These documents contain information that the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent.

## **United States Patents**

- 1. U.S. Patent No. 6,372,892 B1, issued April 16, 2002.
- 2. U.S. Patent No. 6,365,726 B1, issued April 2, 2002.
- 3. U.S. Patent No. 6,339,141 B1, issued January 15, 2002

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art

for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

The present Disclosure Statement is being submitted in compliance with 37 CFR 1.56 insofar as an Examiner might consider any of the cited documents important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,

Dated: November 12, 2003

Sherri L. Oslick, Ph.D.

Shewil Darick

Reg. No. 52,087

U.S. Department of Commerce Form PTO-1449 Patent and Trademark Office 00-1213; A-636-B **INFORMATION DISCLOSURE ESTATEMENT BY APPLICANT** NOV 1 2 2003

PAL

Atty. Docket No. Serial No.

09/724,583

Applicant: Saris, et al.

Filing Date:

November 28, 2000

Group: 1646

# **U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initial	No.	Document Number	Filing Date	Name	Publication Date if Appropriate

## **U.S. PATENT DOCUMENTS**

Examiner Initial	No.	Document Number	Date	Name	Class	Subclass	Filing Date
	1.	6,372,892 B1	4/16/02	Ballinger			
	2.	6,365,726 B1	4/2/02	Ballinger			
	3.	6,339,141 B1	1/15/02	Ballinger			

#### FOREIGN PATENT DOCUMENTS

Examiner Initial	No.	Document Number	Date	Country	Class	Subclass	Transl Yes	lation No

OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

Examiner Initial	No.	

Examiner	Date Considered